Trial Profile
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms CONTI-PV; Continuation; CONTINUATION-PV
- Sponsors AOP Orphan Pharmaceuticals AG
- 12 Dec 2023 Results assessing treatment response in PROUD-PV and CONTINUATION-PV trials, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 07 Dec 2023 According to AOP Orphan Pharmaceuticals GmbH media release, data from the study will Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting
- 19 Sep 2023 According to a an AOP Orphan Pharmaceuticals AG media release, data from CONTINUATION-PV and PROUD-PV presented at the Annual Meeting of the European Hematology Association and published in the journal Leukemia.